Kathryn Dzintars, Pharm.D., BCPS



  • The FDA issued an Emergency Use and Authorization (EUA) permitting the use of vilobelimab for the treatment of coronavirus disease 19 (COVID-19) in hospitalized adults (>18 years of age) when initiated within 48 hours of receiving invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO).

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: September 3, 2023